ATNAHS PHARMA UK LIMITED

• ◆

  3 officer resignations in last 12 months

  Multiple officers have left the board recently — see the People section for who.

1. ATNAHS PHARMA UK LIMITED 2014-04-23 → present
2. ATNAHS UK HOLDINGS LIMITED 2013-11-25 → 2014-04-23

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

Deloitte LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Directors believe that overall, the Pharmanovia Holdco Group, which is the largest and smallest Group of undertakings to consolidate these financial statements, is well placed to manage its business risks successfully, and future forecasts show sufficient headroom that has led to the conclusion that adopting the going concern basis of accounting is appropriate.”

Group structure

1. ATNAHS PHARMA UK LIMITED · parent
   1. Marlborough Pharmaceutical Limited 100% · UK
   2. Atnahs Pharma US Limited 100% · UK
   3. Bone Guardian Limited 100% · UK
   4. Atnahs Pharma Australia Pty Limited 100% · Australia
   5. Pharmanovia A/S 100% · Denmark
   6. Atnahs Pharma Denmark ApS 100% · Denmark
   7. Pharmanovia India Private Limited 100% · India
   8. Pharmanovia Italy S.R.L 100% · Italy
   9. Atnahs Pharma Switzerland AG 100% · Switzerland
   10. Pharmanovia APAC PTE Ltd 100% · Singapore
   11. Pharmanovia Korea Limited 100% · Korea
   12. Pharmanovia Belgium B.V 100% · Belgium
   13. Pharmanovia (Shanghai) pharmaceutical consulting Co,. Ltd 100% · China
   14. Pharmanovia España, S.L. 100% · Spain
   15. Atnahs Pharma France 100% · France
   16. Pharmanovia Pharmanovia GmbH 100% · Germany
   17. Pharmanovia Benelux B.V 100% · Netherlands
   18. Atnahs Pharma Netherlands B.V 100% · Netherlands

Significant events

• “During the financial year ending 31 March 2025, the Group encountered a number of operational and financial challenges, including: Regulatory and operational challenges in China which led to higher-than-expected in-market inventory, suppressing primary and secondary sales; Supply challenges in Mexico, which disrupted primary sales; Reduced demand in several markets including Italy and Spain where inventory already in the channel was utilised to meet the lower demand of primary and secondary sales reducing working capital in these markets. These factors impacted the Group's performance for the year ended 31 March 2025 and required management to implement responsive measures to mitigate their effects. The group has embarked on a transformation program which includes a change of executive leadership positions, right sizing the organisation for the new outlook and optimising its commercial and M&A investments given the significant impairments recognised in the current financial year.”
• “On 1 August 2025, the Company sold the licenses related to its Greater China Osteoporosis business to Bone Guardian Limited, a subsidiary undertaking for €54,205k in consideration of share capital in the Bone Guardian Limited Business. No gain or loss was made on the sale of the intangible assets.”
• “On 1 August 2025, the Company sold the share capital of Pharmanovia (Shanghai) pharmaceutical consulting Co,. Ltd to Bone Guardian Limited for €2,328k. No gain or loss was made on the sale of the company.”
• “As at 31 July 25, the Company had drawn down a net balance of €49,390k from its revolving credit facility with Pharmanovia Bidco Limited.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

14

last 12 months

Capital events

0

last 24 months

Officers appointed

3

last 12 months

Officers resigned

3

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.